Avalo Therapeutics, Inc. 8-K

What Happened
Avalo Therapeutics, Inc. (AVTX) filed an 8‑K on June 23, 2026 announcing that the Board appointed Ron Philip as a director effective that same date. Mr. Philip will serve until the Company’s 2027 Annual Meeting of Stockholders (or until a successor is elected) and joins the Compensation Committee and the Science, Development and Commercial Advisory Committee immediately upon appointment.

Key Details

• Appointment date: June 23, 2026; term runs through the 2027 Annual Meeting of Stockholders.
• Equity compensation: a non‑qualified stock option to purchase 40,200 shares granted June 23, 2026; vests in three substantially equal installments on each of the first, second and third anniversaries, subject to continued service.
• Exercise price: equal to the closing price of Avalo’s common stock on the Nasdaq Capital Market on June 23, 2026.
• Governance/independence: no related‑party transactions reported; Board believes Mr. Philip meets Nasdaq Rule 5605(a)(2) independence requirements. He will enter Avalo’s standard indemnification agreement.

Why It Matters
This is a governance update—Avalo added an experienced biotech executive with recent CEO and board roles (CREATE Medicines, Orbital Therapeutics, Spark Therapeutics, Pfizer) to strengthen oversight of compensation and science/development strategy. The option grant aligns his interests with shareholders but vests over three years and is subject to continued service. There is no change to executive management or reported financial results in this filing.